CD79A and COVID-19: Antibodies directed against the RBD of the S protein demonstrate neutralizing ability and SARS-CoV-2 neutralizing immunoglobulins (Ig)A, IgM and IgG have been identified in COVID-19 patients (39) with IgM being produced first (38, 40).